For the past ~7 years, Chevron's (CVX) less than stellar returns on capital have tested investors' patience. This period of weak returns is the result of years of heavy investment followed by years of low commodity prices. CVX, however, has reset its cost structure. Massive offshore projects that cost billions of dollars over several years [...]
Fortive (FTV) was spun-off from Danaher in July 2016 at which time it had reported FY2015 annual revenue of ~$6.2B. After FTV became a separate publicly traded entity, it has undergone a significant transformation. Source: FTV - Q1 2022 Earnings Presentation - April 28, 2022 Segments of its business have been divested [...]
This is my FFJ Portfolio - April 2022 Report. When Warren Buffett worked for Graham-Newman, his mentor (Ben Graham) advised him that: 'In the short run, the market is a voting machine. In the long run, it is a weighing machine. People have been successful investors because they've stuck with successful companies. Sooner or later [...]
Rollins, Inc. (ROL) might not be a recognizable name. Mention Orkin, however, and that is a different story. I think just about everyone in North America has at least seen the Orkin logo at some point. ROL acquired Orkin for $62 million in 1964; the evolution of Rollins is found here. Today, ROL is [...]
In my August 14th Brookfield Asset Management (BAM) stock analysis I disclose the purchase of additional BAM shares through various accounts. In that post, I conclude: 'I have no interest in investing in cryptocurrencies, SPACs, or complex derivative products. I do, however, want exposure to alternative assets thus my reason for investing in BAM.' After [...]
I have been a Visa (V) shareholder almost from the day it went public on March 18, 2008. Over the years I have also increased my exposure. My most recent purchase was made in early March 2022 at which time I acquired shares at ~$195. The number of shares acquired was not meaningful so I [...]
A year has elapsed since I last reviewed Otis Worldwide Corporation (OTIS). At the time, I envisioned a broad market sell-off would lead to a more attractive valuation. Following that post, OTIS's share price skyrocketed and its valuation deteriorated. In early February 2022, I took a quick look at OTIS but still did not like [...]
In my October 20, 2021 post, I disclose a new 30 share position in Intuitive Surgical (ISRG) in a 'Core' account in the FFJ Portfolio and conclude that post by stating that 'Despite shares being grossly overvalued, I think ISRG will be a far more valuable company several years into the future.' I followed [...]
On April 21, 2022 I published my Danaher (DHR) - Creating Long-Term Shareholder Value post. In that post, I touch upon why I deem it to be an attractive long-term investment. I conclude by stating my intent to acquire additional shares even though its valuation is slightly less attractive than at the time of [...]
Danaher (DHR) is creating long-term shareholder value. Over a 10-year timeframe, the average annual total return with the reinvestment of dividends is 22.07% and 21.73% without the reinvestment of dividends. In contrast, the returns from the S&P500 are 14.69% and 13.65% (source: www.tickertech.com). Despite viewing DHR's valuation to be somewhat rich, I initiated a small [...]
